demonstrated that a combined therapy of avasimibe, the inhibitor of Acyl-coenzyme A:cholesterol acyltransferase1 (ACAT1) which is a crucial cholesterol esterification enzyme (156), with an anti-PD-1 antibody offers better efficacy than monotherapies in controlling tumor progression of melanoma-bearing mice (155). Here, PDCD1 is linked to neoplasm.